secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001213900-23-064241
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix Q2 net loss widens to $11.3M; DefenCath NDA PDUFA date Nov 15, 2023
----------------------------------------------------------------------------

- Net loss of $11.3M ($0.25 per share) vs $7.6M loss in Q2 2022, driven by increased R&D and SG&A.
- Cash and short-term investments $52.4M at June 30; after July equity offering pro forma cash ~$95M.
- DefenCath NDA accepted with PDUFA target date of November 15, 2023; CMS set NTAP up to $17,111 if approved.
- Operating expenses increased 43% to $11.8M; R&D up 49% to $4.8M; SG&A up 39% to $7.0M.
- Strategic initiative with Boston Medical Center to assess CRBSI incidence and health disparities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023064241/0001213900-23-064241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023064241/ea183017-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-064241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer